Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

BEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma

Open access

Abstract

Background : Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Optimal treatment decisions are challenging, and existing treatment allocation frameworks may not fully reflect the evolving therapeutic landscape or contemporary clinical practices in North America. Methods : Using a modified Delphi process, a multidisciplinary panel of 20 North American experts in hepatology, medical oncology, surgery, radiology, and radiation oncology developed a consensus-based treatment framework for HCC, termed the BEACON-HCC system. The framework was informed by current evidence and expert opinion through iterative discussion and voting. In a pilot study using 29 real-world patient cases, we assessed concordance between external expert recommendations and BEACON-HCC recommendations and Barcelona Clinic Liver Cancer (BCLC) 2025 treatment recommendations. Results : The BEACON-HCC treatment allocation framework diverges from prior frameworks by incorporating nuanced clinical features such as degree of intrahepatic tumor burden and vascular invasion, and adverse tumor prognostic markers, to align treatment allocation with tumor biology and therapeutic potential. Key innovations include the incorporation of emerging modalities such as external beam radiation therapy (EBRT), transarterial radioembolization (TARE), and systemic-locoregional combination therapies. In the pilot exercise, expert treatment decisions showed 96.6% concordance with BEACON-HCC recommendations and 72.4% concordance with BCLC recommendations. Conclusions : BEACON-HCC is a consensus-based framework for treatment allocation that incorporates the expanding range of therapeutic options available to patients in the North American HCC population. Expert treatment decisions showed a high concordance with the BEACON-HCC system; further validation using empiric clinical data is planned through the HCC-Live Consortium.

Overview

Integrity signals

Registry

Crossref · 10.1097/hep.0000000000001834

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 66 references

Research works printed but not linked: 3

  1. Tabrizian, 2022, Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma, JAMA Surg, 157, 779
  2. Finn, 2024, Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in IMbrave150, Liver Cancer, 13, 655
  3. Abou-Alfa, 2021, Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma, N Engl J Med Evidence, 1, 1

Cited by

See all 7

Metadata

Authors
Singal, A. G., Agopian, V. G., Dawson, L. A., El-Khoueiry, A., Finn, R. S., Halazun, K., Heimbach, J. K., Kelley, R. K., Kim, E., Kulik, L., Mehta, N., Mendiratta-Lala, M., Meyer, J., Parikh, N. D., Pillai, A., Salem, R., Sapisochin, G., Tabrizian, P., Yopp, A., Yarchoan, M., & on behalf of HCC-Live Steering Committee
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • University of California, Los Angeles (US)
  • University of Toronto (CA)
  • University of Southern California (US)
  • NYU Langone Health (US)
  • Mayo Clinic (US)
  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA
  • Icahn School of Medicine at Mount Sinai (US)
  • Northwestern University (US)
  • University of California, San Francisco (US)
  • Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
  • Johns Hopkins University (US)
  • University of Michigan (US)
  • University of Chicago (US)
  • Department of Abdominal, General Surgery and Liver Transplantation, Hospital Universitario Vall d´Hebron, Barcelona, Spain
  • Mount Sinai Hospital (US)
Venue
Hepatology
Published
2026-08-07
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W7201851864
Cited by
7
References
66
Citations by year
2026: 7
FWCI
28.22
Type
journal article
Language
en
Open access
Locations
  • Hepatology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Social Sciences › Sociology and Political Science › Delphi Technique in Research
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
hepatocellular carcinoma, treatment allocation, external beam radiotherapy, radioembolization, vascular invasion, prognostic factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1097/hep.0000000000001834
The paper
Singal, A. G., Agopian, V. G., Dawson, L. A., El-Khoueiry, A., Finn, R. S., Halazun, K., Heimbach, J. K., Kelley, R. K., Kim, E., Kulik, L., Mehta, N., Mendiratta-Lala, M., Meyer, J., Parikh, N. D., Pillai, A., Salem, R., Sapisochin, G., Tabrizian, P., Yopp, A., . . . on behalf of HCC-Live Steering Committee. (2026). BEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma. Hepatology. https://doi.org/10.1097/hep.0000000000001834

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.